Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The Lancet Commission on prostate cancer: planning for the surge in cases
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
Molecular imaging in oncology: Current impact and future directions
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer …
Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and …
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Contemporary radiotherapy: present and future
Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …
continues to have a key role across the disease spectrum in nearly every cancer. However …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial
Importance Despite evidence demonstrating an overall survival benefit with up-front
hormone therapy in addition to established synergy between hormone therapy and …
hormone therapy in addition to established synergy between hormone therapy and …
[HTML][HTML] Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer …
Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …
treatment options have improved outcomes in advanced prostate cancer. However, we still …
Genomic and phenotypic heterogeneity in prostate cancer
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …
heterogeneous disease. Primary prostate cancers are often multifocal, having …